Meeting of the Advisory Committee on Blood and Tissue Safety and Availability, 4922-4923 [2015-01680]
Download as PDF
4922
Federal Register / Vol. 80, No. 19 / Thursday, January 29, 2015 / Notices
These applications for review will be
addressed in the future. Accordingly,
this docket will remain open.
10. Upon publication of document DA
14–1871 in the Federal Register, these
proceedings will be terminated in the
Electronic Comment Filing System
(ECFS). The record in the terminated
proceedings will remain part of the
Commission’s official records, and the
various pleadings, orders, and other
documents in these dockets will
continue to be accessible to the public,
post-termination.
Regulatory Flexibility Act
11. The Commission’s action does not
require notice and comment and is not
subject to the Regulatory Flexibility Act
of 1980, as amended. See 5 U.S.C.
601(2), 603(a). The Commission
nonetheless notes that it anticipates that
the rules adopted will not have a
significant economic impact on a
substantial number of small entities. As
described above, the Commission
primarily changes its own internal
procedures and organizations and does
not impose substantive new
responsibilities on regulated entities.
There is no reason to believe
termination of certain dormant
proceedings would impose significant
costs on parties to Commission
proceedings. To the contrary, the
Commission takes the actions herein
with the expectation that overall they
will make dealings with the
Commission quicker, easier, and less
costly for entities of all size.
Ordering Clauses
Pursuant to the authority contained in
sections 4(i), and 4(j) of the
Communications Act, 47 U.S.C. 154(i)
and (j), and § 0.141 of the Commission’s
rules, that the proceedings set forth in
document DA 14–1871 are terminated.
mstockstill on DSK4VPTVN1PROD with NOTICES
Sunshine Act Notice
Sarah L. Stewart,
Deputy General Counsel.
January 26, 2015.
[FR Doc. 2015–01808 Filed 1–27–15; 4:15 pm]
2:00 p.m., Thursday,
January 29, 2015.
PLACE: The Richard V. Backley Hearing
Room, Room 511N, 1331 Pennsylvania
Avenue NW., Washington, DC 20004
(enter from F Street entrance).
STATUS: Closed.
MATTERS TO BE CONSIDERED: It was
determined by a unanimous vote of the
Commissioners that the Commission
consider and act upon the following in
closed session: Brody Mining, LLC v.
Secretary of Labor, Docket Nos. WEVA
2014–82–R, et al. (Issues include
whether to grant or deny the Secretary
of Labor’s Emergency Motion for Stay of
ALJ’s Order Dismissing Pattern-ofViolations Notice.) This is the earliest
practicable time that notice of the closed
meeting could be provided.
CONTACT PERSON FOR MORE INFO:
Emogene Johnson (202) 434–9935/(202)
708–9300 for TDD Relay/1–800–877–
8339 for toll free.
BILLING CODE 6735–01–P
TIME AND DATE:
Sarah L. Stewart,
Deputy General Counsel.
[FR Doc. 2015–01726 Filed 1–27–15; 11:15 am]
BILLING CODE 6735–01–P
FEDERAL MINE SAFETY AND HEALTH
REVIEW COMMISSION
Sunshine Act Meeting
11:00 a.m., Thursday,
February 5, 2015.
PLACE: The Richard V. Backley Hearing
Room, Room 511N, 1331 Pennsylvania
Avenue NW., Washington, DC 20004
(enter from F Street entrance).
STATUS: Open.
MATTERS TO BE CONSIDERED: The
Commission will consider and act upon
the following in open session: Mill
Branch Coal Corp. v. Secretary of Labor,
Docket Nos. VA 2012–435–R et al.
(Issues include whether the
Administrative Law Judge erred in
upholding an imminent danger order.)
Any person attending this meeting
who requires special accessibility
features and/or auxiliary aids, such as
sign language interpreters, must inform
the Commission in advance of those
needs. Subject to 29 CFR 2706.150(a)(3)
and 2706.160(d).
CONTACT PERSON FOR MORE INFO:
Emogene Johnson (202) 434–9935/(202)
TIME AND DATE:
The Commission will not send a copy
of document DA 14–1871 pursuant to
the Congressional Review Act, see 5
U.S.C. 801(a)(1)(A) because the
Commission is not adopting, amending,
revising, or deleting any rules.
Federal Communications Commission.
Kris Anne Monteith,
Acting Chief, Consumer and Governmental
Affairs Bureau.
[FR Doc. 2015–01702 Filed 1–28–15; 8:45 am]
BILLING CODE 6712–01–P
18:16 Jan 28, 2015
708–9300 for TDD Relay/1–800–877–
8339 for toll free.
January 27, 2015.
Congressional Review Act
VerDate Sep<11>2014
FEDERAL MINE SAFETY AND HEALTH
REVIEW COMMISSION
Jkt 235001
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
FEDERAL MINE SAFETY AND HEALTH
REVIEW COMMISSION
Sunshine Act Meeting
January 27, 2015.
10:00 a.m., Thursday,
February 5, 2015.
PLACE: The Richard V. Backley Hearing
Room, Room 511N, 1331 Pennsylvania
Avenue NW., Washington, DC 20004
(enter from F Street entrance).
STATUS: Open.
MATTERS TO BE CONSIDERED: The
Commission will consider and act upon
the following in open session: Secretary
of Labor v. Jim Walter Resources, Inc.,
Docket No. SE 2011–407–R; and
Secretary of Labor v. Jim Walter
Resources, Inc., Docket No. SE 2012–
681–R (Issues include whether the
Administrative Law Judges erred in
upholding certain imminent danger
orders.)
Any person attending this meeting
who requires special accessibility
features and/or auxiliary aids, such as
sign language interpreters, must inform
the Commission in advance of those
needs. Subject to 29 CFR 2706.150(a)(3)
and 2706.160(d).
CONTACT PERSON FOR MORE INFO:
Emogene Johnson (202) 434–9935/(202)
708–9300 for TDD Relay/1–800–877–
8339 for toll free.
TIME AND DATE:
Sarah L. Stewart,
Deputy General Counsel.
[FR Doc. 2015–01805 Filed 1–27–15; 4:15 pm]
BILLING CODE 6735–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Advisory Committee on
Blood and Tissue Safety and
Availability
Department of Health and
Human Services, Office of the Secretary,
Office of the Assistant Secretary for
Health.
ACTION: Notice.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the U.S.
Department of Health and Human
Services is hereby giving notice that the
Advisory Committee on Blood and
SUMMARY:
E:\FR\FM\29JAN1.SGM
29JAN1
mstockstill on DSK4VPTVN1PROD with NOTICES
Federal Register / Vol. 80, No. 19 / Thursday, January 29, 2015 / Notices
Tissue Safety and Availability
(ACBTSA) will hold a meeting. The
meeting will be open to the public.
DATES: The meeting will take place
Tuesday April 7, 2105, from 8:00 a.m.–
4:00 p.m. and Wednesday April 8, 2015,
from 8:00 a.m.–3:30 p.m.
ADDRESSES: NIH Conference Room, 5635
Fishers Lane, Rockville, MD 20892.
FOR FURTHER INFORMATION CONTACT: Mr.
James Berger, Designated Federal Officer
for the ACBTSA, Senior Advisor for
Blood and Tissue Policy, Office of the
Assistant Secretary for Health,
Department of Health and Human
Services, 1101 Wootton Parkway, Suite
250, Rockville, MD 20852. Phone: (240)
453–8803; Fax (240) 453–8456; Email
ACBTSA@hhs.gov.
SUPPLEMENTARY INFORMATION: The
ACBTSA provides advice to the
Secretary through the Assistant
Secretary for Health. The Committee
advises on a range of policy issues to
include: (1) Identification of public
health issues through surveillance of
blood and tissue safety issues with
national biovigilance data tools; (2)
identification of public health issues
that affect availability of blood, blood
products, and tissues; (3) broad public
health, ethical and legal issues related to
the safety of blood, blood products, and
tissues; (4) the impact of various
economic factors (e.g., product cost and
supply) on safety and availability of
blood, blood products, and tissues; (5)
risk communications related to blood
transfusion and tissue transplantation;
and (6) identification of infectious
disease transmission issues for blood,
organs, blood stem cells and tissues.
The Committee has met regularly since
its establishment in 1997.
The ACBTSA has made previous
recommendations on the need to
improve tissue tracking and traceability.
These recommendations focused on
tracking adverse events, creating a
unique identifier for each donor, and
improving patient outcomes. Past
recommendations made by the ACBTSA
may be viewed at www.hhs.gov/
bloodsafety.
The focus of the meeting will be to
address current issues in tracking and
traceability of tissue recovered from
deceased donors. The discussion will
focus on pertinent federal and state
regulations, other mechanisms that
impact tissue tracking and traceability,
and current gaps in this area. Presenters
will represent a wide range of
government and non-government
stakeholders, including federal agencies,
accreditation organizations, tissue and
eye banks, healthcare facilities, and
medical practitioners.
VerDate Sep<11>2014
18:16 Jan 28, 2015
Jkt 235001
The public will have an opportunity
to present their views to the Committee
during a public comment session
scheduled for April 8, 2015. Comments
will be limited to five minutes per
speaker and must be pertinent to the
discussion. Pre-registration is required
for participation in the public comment
session. Any member of the public who
would like to participate in this session
is encouraged to contact the Designated
Federal Officer at his/her earliest
convenience to register for time (limited
to 5 minutes) ; registration must be
completed prior to close of business on
April 1, 2015. If it is not possible to
provide 30 copies of the material to be
distributed at the meeting, then
individuals are requested to provide a
minimum of one (1) copy of the
document(s) to be distributed prior to
the close of business on April 1, 2015.
It is also requested that any member of
the public who wishes to provide
comments to the Committee utilizing
electronic data projection submit the
necessary material to the Designated
Federal Officer prior to the close of
business on April 1, 2015.
Dated: January 22, 2015.
James J. Berger,
Senior Advisor for Blood and Tissue Safety
Policy.
[FR Doc. 2015–01680 Filed 1–28–15; 8:45 am]
BILLING CODE 4150–41–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Nominations to the Advisory
Committee on Blood and Tissue Safety
and Availability
Office of the Secretary, Office
of the Assistant Secretary for Health,
Department of Health and Human
Services.
ACTION: Notice.
AGENCY:
The Office of Assistant
Secretary for Health (OASH) is seeking
nominations of qualified individuals to
be considered for appointment as
members of the Advisory Committee on
Blood and Tissue Safety and
Availability (ACBTSA). ACBTSA is a
Federal advisory committee within the
Department of Health and Human
Services. Management support for the
activities of this Committee is the
responsibility of the OASH. The
qualified individuals will be nominated
to the Secretary of Health and Human
Services for consideration of
appointment as members of the
ACBTSA. Members of the Committee,
including the Chair, are appointed by
the Secretary. Members are invited to
SUMMARY:
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
4923
serve on the Committee for up to fouryear terms.
DATES: All nominations must be
received no later than 4:00 p.m. EDT on
March 2, 2015, at the address listed
below.
All nominations should be
mailed or delivered to Mr. James Berger,
Senior Advisor for Blood and Tissue
Policy; Office of Assistant Secretary for
Health; Department of Health and
Human Services; 1101 Wootton
Parkway, Suite 250; Rockville, MD
20852. Telephone: (240) 453–8803; Fax
(240) 453–8456; Email ACBTSA@
hhs.gov.
ADDRESSES:
Mr.
James Berger, Senior Advisor for Blood
and Tissue Policy. Contact information
for Mr. Berger is provided above.
A copy of the Committee charter and
roster of the current membership can be
obtained by contacting Mr. Berger or by
accessing the ACBTSA Web site at
https://www.hhs.gov/bloodsafety. https://
www.hhs.gov/bloodsafety.
SUPPLEMENTARY INFORMATION: The
ACBTSA shall provide advice to the
Secretary through the Assistant
Secretary for Health. The Committee
shall advise on a range of policy issues
to include: (1) Identification of public
health issues through surveillance of
blood and tissue safety issues with
national biovigilance data tools; (2)
identification of public health issues
that affect availability of blood, blood
products, and tissues; (3) broad public
health, ethical and legal issues related to
the safety of blood, blood products, and
tissues; (4) the impact of various
economic factors (e.g., product cost and
supply) on safety and availability of
blood, blood products, and tissues; (5)
risk communications related to blood
transfusion and tissue transplantation;
and (6) identification of infectious
disease transmission issues for blood,
organs, blood stem cells and tissues.
The Committee consists of 23 voting
members. The Committee composition
includes 14 public members, including
the Chair, and nine (9) individuals
designated to serve as official
representative members. The public
members are selected from state and
local organizations, patient advocacy
groups, provider organizations,
academic researchers, ethicists,
physicians, surgeons, scientists, risk
communication experts, consumer
advocates, and from among
communities of persons who are
frequent recipients of blood or blood
products or who have received tissues
or organs. The nine individuals who are
appointed as official representatives are
FOR FURTHER INFORMATION CONTACT:
E:\FR\FM\29JAN1.SGM
29JAN1
Agencies
[Federal Register Volume 80, Number 19 (Thursday, January 29, 2015)]
[Notices]
[Pages 4922-4923]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-01680]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the Advisory Committee on Blood and Tissue Safety and
Availability
AGENCY: Department of Health and Human Services, Office of the
Secretary, Office of the Assistant Secretary for Health.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: As stipulated by the Federal Advisory Committee Act, the U.S.
Department of Health and Human Services is hereby giving notice that
the Advisory Committee on Blood and
[[Page 4923]]
Tissue Safety and Availability (ACBTSA) will hold a meeting. The
meeting will be open to the public.
DATES: The meeting will take place Tuesday April 7, 2105, from 8:00
a.m.-4:00 p.m. and Wednesday April 8, 2015, from 8:00 a.m.-3:30 p.m.
ADDRESSES: NIH Conference Room, 5635 Fishers Lane, Rockville, MD 20892.
FOR FURTHER INFORMATION CONTACT: Mr. James Berger, Designated Federal
Officer for the ACBTSA, Senior Advisor for Blood and Tissue Policy,
Office of the Assistant Secretary for Health, Department of Health and
Human Services, 1101 Wootton Parkway, Suite 250, Rockville, MD 20852.
Phone: (240) 453-8803; Fax (240) 453-8456; Email ACBTSA@hhs.gov.
SUPPLEMENTARY INFORMATION: The ACBTSA provides advice to the Secretary
through the Assistant Secretary for Health. The Committee advises on a
range of policy issues to include: (1) Identification of public health
issues through surveillance of blood and tissue safety issues with
national biovigilance data tools; (2) identification of public health
issues that affect availability of blood, blood products, and tissues;
(3) broad public health, ethical and legal issues related to the safety
of blood, blood products, and tissues; (4) the impact of various
economic factors (e.g., product cost and supply) on safety and
availability of blood, blood products, and tissues; (5) risk
communications related to blood transfusion and tissue transplantation;
and (6) identification of infectious disease transmission issues for
blood, organs, blood stem cells and tissues. The Committee has met
regularly since its establishment in 1997.
The ACBTSA has made previous recommendations on the need to improve
tissue tracking and traceability. These recommendations focused on
tracking adverse events, creating a unique identifier for each donor,
and improving patient outcomes. Past recommendations made by the ACBTSA
may be viewed at www.hhs.gov/bloodsafety.
The focus of the meeting will be to address current issues in
tracking and traceability of tissue recovered from deceased donors. The
discussion will focus on pertinent federal and state regulations, other
mechanisms that impact tissue tracking and traceability, and current
gaps in this area. Presenters will represent a wide range of government
and non-government stakeholders, including federal agencies,
accreditation organizations, tissue and eye banks, healthcare
facilities, and medical practitioners.
The public will have an opportunity to present their views to the
Committee during a public comment session scheduled for April 8, 2015.
Comments will be limited to five minutes per speaker and must be
pertinent to the discussion. Pre-registration is required for
participation in the public comment session. Any member of the public
who would like to participate in this session is encouraged to contact
the Designated Federal Officer at his/her earliest convenience to
register for time (limited to 5 minutes) ; registration must be
completed prior to close of business on April 1, 2015. If it is not
possible to provide 30 copies of the material to be distributed at the
meeting, then individuals are requested to provide a minimum of one (1)
copy of the document(s) to be distributed prior to the close of
business on April 1, 2015. It is also requested that any member of the
public who wishes to provide comments to the Committee utilizing
electronic data projection submit the necessary material to the
Designated Federal Officer prior to the close of business on April 1,
2015.
Dated: January 22, 2015.
James J. Berger,
Senior Advisor for Blood and Tissue Safety Policy.
[FR Doc. 2015-01680 Filed 1-28-15; 8:45 am]
BILLING CODE 4150-41-P